Pacira Pharmaceuticals Inc PCRX Financial and Strategic SWOT Analysis Review [Report Updated: 02052019] Prices from USD $110

12:42 EST 4 Dec 2019 | BioPortfolio Reports

Pacira Pharmaceuticals Inc PCRX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Pacira Pharmaceuticals Inc Pacira discovers, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel bupivacaine liposome injectable suspension is an amidetype local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its other products developed under partnerships include DepoCyt cytarabine liposome injection for lymphomatous meningitis; and Nocita bupivacaine liposome injectable suspension for surgical infiltration in dogs. Its products are used by hospitals and ambulatory surgery centers. The company sells its products through copromotion agreements and supply agreements with other pharmaceutical companies. Pacira is headquartered in Parsippany, New Jersey, the US.

Pacira Pharmaceuticals Inc Key Recent Developments

Apr 02,2019 Pacira Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference

Mar 06,2019 Pacira to acquire medical device maker Myoscience for $220m

Feb 28,2019 Pacira reports record fourth quarter and full year revenues

Feb 12,2019 Pacira Pharmaceuticals Expands Manufacturing in UK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Pacira Pharmaceuticals Inc PCRX Financial and Strategic SWOT Analysis Review [Report Updated: 02052019] Prices from USD $110


More From BioPortfolio on "Pacira Pharmaceuticals Inc PCRX Financial and Strategic SWOT Analysis Review [Report Updated: 02052019] Prices from USD $110"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Anesthesia is the loss of feeling or sensation in all or part of the body. It may result from damage to nerves or can be induced by an anesthetist (a medical professional) using anesthetics such as thiopental or propofol or sevoflurane during a surgical ...